Show simple item record

dc.contributor.authorMarques, T. M.*
dc.contributor.authorPatterson, E.*
dc.contributor.authorWall, Rebecca*
dc.contributor.authorO'Sullivan, Orla*
dc.contributor.authorFitzgerald, Gerald F*
dc.contributor.authorCotter, Paul D.*
dc.contributor.authorDinan, Timothy G.*
dc.contributor.authorCryan, John F.*
dc.contributor.authorRoss, R Paul*
dc.contributor.authorSTANTON, CATHERINE*
dc.date.accessioned2016-07-08T15:59:11Z
dc.date.available2016-07-08T15:59:11Z
dc.date.issued26/05/2016
dc.identifier.citationT.M. Marques, E. Patterson, R. Wall, O. O’ Sullivan, G.F. Fitzgerald, P.D. Cotter, T.G. Dinan, J.F, Cryan, J.F, Ross, R. P., Stanton, C. Influence of GABA and GABA-producing Lactobacillus brevis DPC 6108 on the development of diabetes in a streptozotocin rat model. Beneficial Microbes: 7 (3) - Pages: 409 - 420. DOI: http://dx.doi.org/10.3920/BM2015.0154en_GB
dc.identifier.urihttp://hdl.handle.net/11019/1032
dc.descriptionpeer-revieweden_GB
dc.description.abstractThe aim of this study was to investigate if dietary administration of γ-aminobutyric acid (GABA)-producing Lactobacillus brevis DPC 6108 and pure GABA exert protective effects against the development of diabetes in streptozotocin (STZ)-induced diabetic Sprague Dawley rats. In a first experiment, healthy rats were divided in 3 groups (n=10/group) receiving placebo, 2.6 mg/kg body weight (bw) pure GABA or L. brevis DPC 6108 (~109microorganisms). In a second experiment, rats (n=15/group) were randomised to five groups and four of these received an injection of STZ to induce type 1 diabetes. Diabetic and non-diabetic controls received placebo [4% (w/v) yeast extract in dH2O], while the other three diabetic groups received one of the following dietary supplements: 2.6 mg/kg bw GABA (low GABA), 200 mg/kg bw GABA (high GABA) or ~109 L. brevis DPC 6108. L. brevis DPC 6108 supplementation was associated with increased serum insulin levels (P<0.05), but did not alter other metabolic markers in healthy rats. Diabetes induced by STZ injection decreased body weight (P<0.05), increased intestinal length (P<0.05) and stimulated water and food intake. Insulin was decreased (P<0.05), whereas glucose was increased (P<0.001) in all diabetic groups, compared with non-diabetic controls. A decrease (P<0.01) in glucose levels was observed in diabetic rats receiving L. brevis DPC 6108, compared with diabetic-controls. Both the composition and diversity of the intestinal microbiota were affected by diabetes. Microbial diversity in diabetic rats supplemented with low GABA was not reduced (P>0.05), compared with non-diabetic controls while all other diabetic groups displayed reduced diversity (P<0.05). L. brevis DPC 6108 attenuated hyperglycaemia induced by diabetes but additional studies are needed to understand the mechanisms involved in this reduction.en_GB
dc.description.sponsorshipThe authors and their work were supported by the APC Microbiome Institute. The APC Microbiome Institute is funded by Science Foundation Ireland (SFI). This publication has emanated from research supported by a research grant from Science Foundation Ireland (SFI) under Grant Number SFI/12/RC/2273.en_GB
dc.language.isoenen_GB
dc.publisherWageningen Academic Publishersen_GB
dc.relation.ispartofseriesBeneficial Microbes;vol 7
dc.subjectstreptozotocinen_GB
dc.subjecttype-1 diabetes,en_GB
dc.subjectProbioticen_GB
dc.subjectγ-aminobutyric aciden_GB
dc.titleInfluence of GABA and GABA-producing Lactobacillus brevis DPC 6108 on the development of diabetes in a streptozotocin rat modelen_GB
dc.typeArticleen_GB
dc.identifier.doihttp://dx.doi.org/10.3920/BM2015.0154
dc.contributor.sponsorScience Foundation Ireland
dc.contributor.sponsorGrantNumberSFI/12/RC/2273


Files in this item

Thumbnail
Name:
BM2015 post print.pdf
Size:
971.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record